Advertisement

Advertisement

AVIR Stock Latest News

Atea Pharmaceuticals Eyes 2028 Launch After Strong Phase 3

Company AnnouncementsAtea Pharmaceuticals Eyes 2028 Launch After Strong Phase 3

Atea Pharmaceuticals price target raised to $7 from $6 at Morgan Stanley

PremiumThe Fly

Atea Pharmaceuticals price target raised to $7 from $6 at Morgan Stanley

17d ago

AVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-Earnings

AVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?

24d ago

Atea’s Renal and Hepatic Impairment Study Marks a Key De-Risking Step for AVIR Investors

PremiumCompany Announcements

Atea’s Renal and Hepatic Impairment Study Marks a Key De-Risking Step for AVIR Investors

1M ago

Hold Rating Maintained on Competitive HCV Data but Commercial Uncertainty; Price Target Reiterated at $6

PremiumRatings

Hold Rating Maintained on Competitive HCV Data but Commercial Uncertainty; Price Target Reiterated at $6

1M ago

Atea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints

PremiumThe FlyAtea Pharmaceuticals reports C-BEYOND trial meets primary, secondary endpoints

1M ago

Atea Advances Antiviral Pipeline With New Drug Interaction Study in Opioid Therapy

Company Announcements

Atea Advances Antiviral Pipeline With New Drug Interaction Study in Opioid Therapy

2M ago

Atea Pharmaceuticals initiates AT-587 clinical trial

The Fly

Atea Pharmaceuticals initiates AT-587 clinical trial

2M ago

Atea Pharmaceuticals completes patient enrollment in C-FORWARD trial

PremiumThe Fly

Atea Pharmaceuticals completes patient enrollment in C-FORWARD trial

2M ago

Atea Shareholders Back Directors, Auditors and Executive Pay

PremiumCompany Announcements

Atea Shareholders Back Directors, Auditors and Executive Pay

2M ago

Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call

PremiumCompany Announcements

Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call

4M ago

Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI

PremiumThe Fly

Atea Pharmaceuticals price target raised to $10 from $6 at Evercore ISI

6M ago

Atea Pharmaceuticals’ Earnings Call Flags Pivotal 2026

PremiumCompany AnnouncementsAtea Pharmaceuticals’ Earnings Call Flags Pivotal 2026

6M ago

Is AVIR a Buy, Before Earnings?

Pre-Earnings

Is AVIR a Buy, Before Earnings?

6M ago

Atea Pharmaceuticals presents preclinical results of AT-587

The Fly

Atea Pharmaceuticals presents preclinical results of AT-587

6M ago

Atea Pharmaceuticals to highlight strategic priorities for FY26

PremiumThe Fly

Atea Pharmaceuticals to highlight strategic priorities for FY26

8M ago

Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial

PremiumThe Fly

Atea Pharmaceuticals completes patient enrollment in C-BEYOND Phase 3 trial

9M ago

Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism

PremiumCompany Announcements

Atea Pharmaceuticals’ Earnings Call Highlights Progress and Optimism

10M ago

Atea Pharmaceuticals Advances Antiviral Programs with New Data

PremiumCompany Announcements

Atea Pharmaceuticals Advances Antiviral Programs with New Data

10M ago

AVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?

PremiumPre-EarningsAVIR Earnings Report this Week: Is It a Buy, Ahead of Earnings?

10M ago

Atea Pharmaceuticals announces presentation of data on BEM, RZR

The Fly

Atea Pharmaceuticals announces presentation of data on BEM, RZR

10M ago

Atea Pharmaceuticals’ New HCV Study: Potential Game-Changer?

Company Announcements

Atea Pharmaceuticals’ New HCV Study: Potential Game-Changer?

10M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >